BACKGROUND: The CD4 cell count at which combination antiretroviral therapy should be
started is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of …

Ritonavir is 1 of the 4 potent synthetic HIV protease inhibitors, approved by the US Food and
Drug Administration (FDA) between 1995 and 1997, that have revolutionised HIV therapy …

Background and Methods National surveillance data show recent, marked reductions in
morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS). To …

Background The efficacy and safety of adding a protease inhibitor to two nucleoside
analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We …

Background The new protease inhibitors are potent inhibitors of the human
immunodeficiency virus (HIV), and in combination with other antiretroviral drugs they may be …

Background This double-blind study evaluated treatment with either a single nucleoside or
two nucleosides in adults infected with human immunodeficiency virus type 1 (HIV-1) whose …

Background The introduction of combination antiretroviral therapy and protease inhibitors
has led to reports of falling mortality rates among people infected with HIV-1. We examined …

Context.—Clinical trials have established the efficacy of antiretroviral therapy with double-
and triple-drug regimens for individuals infected with the human immunodeficiency virus …

ContextUse of antiretroviral drugs, including protease inhibitors, for treatment of human
immunodeficiency virus (HIV) infection has been anecdotally associated with hepatotoxicity …

HIV/AIDS not only represents the most severe epidemic in modern times, but also the
greatest public health challenge in history. The response of the scientific community has …